hotspot -WSS

hotspot

author：leisure time 2025-09-28 11:48:53 - browse：3437

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： FDA's Pazdur wants cancer trials to range beyond China alone

leisure time

WSS

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Risky weight loss products often used by teens globally, per study

As JPM 2024 winds down, some health tech firms project optimism

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Kaiser's Risant Health gobbled up Geisinger. Who is next?

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

hotspot

hotspot

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The SUPPORT Act is critical to fighting the opioid crisis

Virginia high school admissions case could be legal follow

HHS names first

23andMe had bad news about my health. I wish a person had delivered it

Generative AI mines health records to identify patients’ social needs

Affirmative action in medical school literally saved lives

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Wildfire smoke exposes gaps in outdoor worker protections

JPM 2024: Verve Therapeutics looks to mainstream genome editing

knowledge

Letters to First Opinion on caregivers, digital health, and more

Idaho abortion case may prompt more restrictions in other states

Let's speed up science by embracing open access publishing

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Ionis drug prevents swelling attacks due to hereditary angioedema

entertainment

leisure time

focus

focus